key: cord-0812572-upqn6dkt
authors: Tammaro, Antonella; Adebanjo, Ganiyat Adenike Ralitsa; Parisella, Francesca Romana; De Marco, Gabriella; Rello, Jordi
title: Local reactions to the second dose of the BNT162 COVID‐19 vaccine
date: 2021-06-01
journal: Dermatol Ther
DOI: 10.1111/dth.15000
sha: ca6ba99467d06c3adb18f13e301de0380330e8f2
doc_id: 812572
cord_uid: upqn6dkt

nan

Dear Editor, Multiple strategies have been implemented worldwide to fight the burden of the pandemic caused by COVID-19, with vaccination being one of the most promising. 1 Notably, the first vaccine to be authorized in Italy was the BNT162 mRNA-based vaccine, which has also been approved in the USA, United Kingdom, and Canada. 1 Vaccine-related adverse reactions are not rare, with the not immunologically mediated ones being the most prevalent. 3 However, serious anaphylactic events are uncommon. 3 The incidence of severe adverse allergic reactions following the administration of the first dose of the BNT162 vaccine seems to be infrequent. 4 In the USA, of almost 2 million people who received the first dose of the vaccine at the end of December 2020, only 0.001% developed anaphylaxis. 4 Compellingly, the majority of the subjects F I G U R E 1 Adverse cutaneous reactions in three women after the second dose of the BNT162 vaccine. (A) A 64-year-old female patient presented a round indented nodule on the site of injection which was hard on palpation. The nodule was surrounded by erythema, painful, and pruritic. (B) Erythematous lesion characterized by multiple vesicles in a 56-year-old woman. The lesion was pruritic and painful. (C) Painful erythematous rash on the chest of a 60-year-old woman who also experienced pruritus on the same area

COVID-19: characteristics and therapeutics

Vaccine-associated hypersensitivity

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine

A severe adverse reaction to omalizumab therapy in chronic spontaneous urticaria

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol? Allergy

Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)

Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2

Adverse reactions to vaccines practice parameter 2012 update